Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
124.30
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
438,807
Open
124.30
Bid (Size)
120.82 (1)
Ask (Size)
120.90 (1)
Prev. Close
124.30
Today's Range
124.30 - 124.30
52wk Range
86.96 - 148.15
Shares Outstanding
N/A
Dividend Yield
1.42%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Today 8:47 EDT
Via
Benzinga
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
Today 8:45 EDT
The thrust of the company's long-term strategy is becoming clearer.
Via
The Motley Fool
Performance
YTD
+21.73%
+21.73%
1 Month
-8.05%
-8.05%
3 Month
-13.97%
-13.97%
6 Month
-3.19%
-3.19%
1 Year
+35.55%
+35.55%
More News
Read More
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
September 26, 2024
Via
Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
September 26, 2024
Via
The Motley Fool
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
September 26, 2024
Via
Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
September 24, 2024
Via
Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
September 23, 2024
Via
Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
September 26, 2024
Via
The Motley Fool
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
September 25, 2024
Via
Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
September 25, 2024
Via
Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
September 25, 2024
Via
Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
September 25, 2024
Via
Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
September 24, 2024
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Via
MarketBeat
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
September 24, 2024
Via
Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
September 24, 2024
Via
The Motley Fool
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
September 23, 2024
Via
Benzinga
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
September 23, 2024
Via
Benzinga
Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
September 22, 2024
Via
Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
Via
Benzinga
3 Stocks That Could Rise on European Bank Interest Rate Cuts
September 22, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
September 21, 2024
Via
Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
September 20, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.